{"id":"W4240488819","doi":"10.1200/jco.2021.39.15_suppl.4541","title":"Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University Health Centre; University of British Columbia","funders":"National Institutes of Health","keywords":"Medicine; Atezolizumab; Bladder cancer; Cystectomy; Clinical endpoint; Internal medicine; Pathological; Urology; Oncology; Surgery; Clinical trial; Cancer; Immunotherapy; Nivolumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0021249,0.001076775,0.001043506,0.0003125586,0.0002715013,0.0005804252,0.0007053827,0.001469025,0.01086459],"category_scores_gemma":[0.0009696855,0.0003721457,0.0009737094,0.0003137756,0.000544549,0.0005309661,0.0004064545,0.002860213,0.00189533],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000576908,"about_ca_system_score_gemma":0.001607898,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005571839,"about_ca_topic_score_gemma":0.002049311,"domain_scores_codex":[0.9995459,0.0002814806,0.00002172538,0.0000466193,0.00003532217,0.00006909791],"domain_scores_gemma":[0.999385,0.00009600454,0.0001642592,0.00004534332,0.00004486711,0.0002644685],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7571701,0.05144025,0.008016639,0.002038935,0.001185368,0.0002583178,0.0002644268,0.001916311,0.02851093,0.0007342197,0.01978836,0.1286761],"study_design_scores_gemma":[0.7306182,0.2524464,0.00748301,0.00007770643,0.0002698122,0.0002383551,0.00004368423,0.000972815,0.002149389,0.0002395289,0.005445755,0.00001541602],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9690092,0.00457377,0.001418892,0.001976582,0.0004925398,0.008593467,0.005842153,0.0002559242,0.00783744],"genre_scores_gemma":[0.9549996,0.002648163,0.003258895,0.003506616,0.0003405826,0.009372814,0.01274858,0.0000615682,0.01306314],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01086459,"threshold_uncertainty_score":0.03634566,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1279401219600671,"score_gpt":0.499667704120935,"score_spread":0.3717275821608679,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}